Latest Press Releases Aug 04 2022 Vertex Reports Second Quarter 2022 Financial Results Read More Jul 22 2022 Vertex Advances VX-548 in Acute and Neuropathic Pain Read More Jul 20 2022 Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease Read More Jul 18 2022 Vertex to Announce Second Quarter 2022 Financial Results on August 4 Read More Jul 11 2022 Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes Read More Jul 05 2022 Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Read More Load More Recent Media Library Items View All Date - Any -20212022 Tags Download LibraryImages Inclusion, Diversity and Equity at Vertex Fact Sheet Download 3 MB Date - Any -20212022 Tags Download LibraryImages Reshma Kewalramani, M.D. Chief Executive Officer and President Download 10 MB Date - Any -20212022 Tags Download LibraryImages Vertex International Headquarters Paddington – Lobby Padding reception entrance Download 915 KB Date - Any -20212022 Tags Download LibraryImages Vertex Logo with Tagline Download 2 MB | 2951 x 1952 Mediainfo@VRTX.com
Jul 20 2022 Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease Read More
Jul 11 2022 Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes Read More
Jul 05 2022 Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Read More
